Along with epigenetic silencing of tumor-suppressor genes [12], in different types of cancer cells, EZH2 upregulation is linked with the transcriptional repression of genes that confer immunogenicity (e.g., MHC I and II) and support the recruitment of effector T cells (e.g., CXCL9 and CXCL10) [24,58,59,60]. The gene discussed is CXCL9; the disease is cancer.